Brazil’s ANVISA approved the Butantan-DV single-dose dengue vaccine, developed by Butantan Institute, showing 91.6 percent efficacy amid record global dengue cases in 2024.
Hot this week
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Get important news delivered directly to your inbox and stay connected!
